Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Accesswire
*Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of..
*Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of..
*Technology offers timely and cost-efficient infection prevention solution for long-term care amidst industry-wide labor..
The CEPI-funded study will evaluate the safety, tolerability, and immunogenicity of IAVI's single dose Lassa fever vaccine..